Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.65 |
| ▸ | CA1 | P00915 | 5/20 | 0.65 |
| ▸ | CA2 | P00918 | 5/20 | 0.65 |
| ▸ | CA9 | Q16790 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6183257 | 0.96 | CA12 (0.66) | CA12CA1CA2CA9MAPT | |
| SCHEMBL25987728 | 0.93 | CA12 (0.57) | CA12CA1CA2CA9MAPT | |
| SCHEMBL30693811 | 0.93 | CA12 (0.57) | CA12CA1CA2CA9MAPT | |
| SCHEMBL17162067 | 0.93 | CA12 (0.57) | CA12CA1CA2CA9MAPT | |
| SCHEMBL25987718 | 0.92 | CA12 (0.67) | CA12CA1CA2CA9MAPT | |
| SCHEMBL114495 | 0.90 | BCHE (0.54) | CA12CA1CA2CA9MAPT | |
| SCHEMBL25837021 | 0.87 | MAPT (0.56) | CA12CA1CA2CA9MAPT | |
| SCHEMBL27356591 | 0.86 | MGLL (0.62) | CA12CA1CA2CA9MAPT | |
| SCHEMBL14907652 | 0.85 | MGLL (0.67) | CA12CA1CA2CA9MAPT | |
| SCHEMBL5418888 | 0.85 | MEN1 (0.55) | CA12CA1CA2CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491178-B2 | Chitosan covalently linked with small molecule integrin antagonist for targeted delivery | HOFFMANN-LA ROCHE, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| WO-2022192162-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
| EP-2806896-B1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN LA ROCHE (CH) | 2018-01-03 | — | — | EP | disclosed |
| US-20150306130-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150306130-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2806896-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013110681-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| US-20130197205-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-7166599-B2 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | disclosed |
| EP-1453516-A2 | NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20030134838-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-17 | — | — | US | disclosed |
| WO-2003032994-A2 | NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | disclosed |
| US-6300368-B1 | FOR THERAPY OF ATRIAL ARRHYTHMIA | MITSUI CHEMICALS, INC. (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-0968999-A1 | Anilide derivatives and antiarrhythmic agents containing the same | Mitsui Chemicals, Inc. (JP) | 2000-01-05 | — | — | EP | disclosed |
| EP-0611003-B1 | Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | MERCK & CO INC (US) | 1997-06-18 | — | — | EP | disclosed |
| US-5451677-A | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity | MERCK & CO., INC. (US) | 1995-09-19 | — | — | US | disclosed |
| EP-0611003-A1 | Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | MERCK & CO. INC. (US) | 1994-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGB4 | CA12 1626/4885CA1 2476/4885CA2 886/4885 |
| US-20130197205-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGA1 | CA12 1549/4885CA1 2382/4885CA2 837/4885 |
| US-20030134838-A1 | Trisubstituted pyrimidines | APP, PSEN1, BACE1 | CA12 4858/4885CA1 3582/4885CA2 4551/4885 |
| US-20050090486-A1 | Trisubstituted pyrimidines | APP, BACE1, PSEN1 | CA12 4667/4885CA1 2718/4885CA2 4045/4885 |
| US-11491178-B2 | Chitosan covalently linked with small molecule integrin antagonist for targeted delivery | ITGB1, ITGA4, ITGB4 | CA12 1626/4885CA1 2476/4885CA2 886/4885 |
| US-20150306130-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGA1 | CA12 1549/4885CA1 2382/4885CA2 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.